Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

145.65
-0.9900-0.68%
Pre-market: 146.200.5500+0.38%07:05 EDT
Volume:4.58M
Turnover:668.09M
Market Cap:180.70B
PE:-55.70
High:147.68
Open:145.46
Low:145.00
Close:146.64
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.86
T/O Rate:0.37%
Dividend:3.22
Dividend Rate:2.21%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.28
PE(LYR):21.48

Loading ...

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Yesterday

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Yesterday

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Yesterday

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS
·
Yesterday

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Yesterday

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS
·
Yesterday

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Yesterday

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Yesterday

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS
·
Yesterday

Movement Alert|Gilead Sciences Falls 3.18% in Regular Trading, Trading at $148.555

Market Focus
·
Sep 08

Movement Alert|Gilead Sciences Falls 3.47% in Pre-Market Trading, Trading at $146.39

Market Focus
·
Sep 08

Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026

Reuters
·
Sep 08

Gilead Sciences (GILD) Receives a Buy from Bernstein

TIPRANKS
·
Sep 08

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 04

Gilead’s Arcus-Backed Cancer Trial Reaches Completion, Setting Up a Key Immuno-Oncology Catalyst

TIPRANKS
·
Sep 04

Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer

Reuters
·
Sep 03

Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares

Reuters
·
Sep 03

Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?

Simply Wall St.
·
Sep 02

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 02

Moderna Inc. Stock Advances 9.9%, Outperforms Peers

Dow Jones
·
Sep 02